AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04524845 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Unloading brace
Description: Participants underwent one session of gait analysis. The experimental protocol was divided in four conditions, the control condition without brace (NO), and then three conditions with the different braces tested in a randomized order.~For each condition, the participant was fitted with the brace by the same experimenter and equipped with 19/20 retro-reflective markers (without/with brace) on the pelvis and the investigated leg for motion analysis. After a short recording in a fixed standing position (static trial), each participant carried out at least three barefoot walking trials of a few meters long at a self-selected pace. The walking trial was validated if a complete gait cycle occurred on the two 90cm x 90 cm force plates recording the ground reaction forces. After each condition, the participant had to assess knee pain.
Study NCT04524845 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rebel Reliever (RR)
Description: Rebel Reliever (RR) (Thuasne, Levallois Perret, France)
Study NCT04524845 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Action Reliever
Description: Action Reliever (AR) (Thuasne, Levallois Perret, France)
Study NCT02489318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Participants will receive apalutamide 240 mg (4 x 60 mg) tablets orally once daily in each 28 day treatment cycles.
Study NCT02489318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive Placebo orally once daily in each 28 day treatment cycles.
Study NCT02368548 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmaceutical Care Program
Description: Intensive pharmaceutical care program, initiated in the emergency department, as described in its corresponding arm intervention description.
Study NCT02368548 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard Care
Description: Standard pharmaceutical care process, initiated at the hospital admission, as described in its corresponding arm intervention description.
Study NCT03084133 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Education Strategy
Description: In the experimental arm of the study (intervention group), a screening information and education system will be implemented. The particularities of the index cases likely to require an adaptation of the device will be collected, analyzed and taken into account (level of health literacy, socio-economic status, level of education, professional activity ...). The analysis and intervention frameworks derived from theories on health behaviors will be mobilized (theory of reasoned action, theory of planned behaviors) and applied in order to reinforce the intention of the target audience. The analysis and intervention frameworks resulting from the educational sciences will be integrated with a competence approach (Aizen, 1991, Denovel, Dufour, Prochaska, 1983, Le Boterf, 2002).
Study NCT03316352 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-assisted paramedian technique spinal anesthesia
Description: Ultrasound-assisted paramedian technique will be used. A preprocedural ultrasound scan will be performed, and skin marking for spinal entry site will be done using ultrasound scan. Spinal anesthesia will be done according to skin marking using ultrasound, via paramedian approach.
Study NCT02489318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen Deprivation Therapy (ADT)
Description: All participants will receive and remain on a stable regimen of ADT (gonadotropin releasing hormone analog \[GnRHa\] or surgical castration). The choice of the GnRHa (agonist or antagonist) will be at discretion of the Investigator. Dosing (dose and frequency of administration) will be consistent with the prescribing information.
Study NCT01612923 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Midwife
Description: gynecological exam and ultrasound and contraceptive advice provided by midwife
Study NCT02834754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab is a monoclonal antibody developed by Millennium Pharmaceuticals, Inc for the treatment of ulcerative colitis and Crohn's disease. It binds to integrin α₄β₇. Blocking the α₄β₇ integrin results in gut-selective anti-inflammatory activity. Vedolizumab was been approved by the Food and Drug Administration (FDA) in 2014 for achieving clinical response, achieving clinical remission, and achieving corticosteroid-free remission in adult patients with moderately to severely active Crohn's disease. We believe that use of vedolizumab constitutes a non-significant risk to the research subject. The dose of vedolizumab administered is 300mg IV
Study NCT02834754 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Currently there are no clinical guidelines and no standard of care for the maintenance of surgically induced remission. There are no medications that have consistently been proven to be efficacious at preventing recurrent Crohn's disease and as such, no active equivalent arm is being used. Due to the lack of effective prophylactic therapy, many physicians and patients opt not to initiate medical therapy after surgery, rather wait until Crohn's disease recurs, or wait to perform a post-operative colonoscopy within 6-12 months of surgery, and decide on initiating Crohn's disease therapy based on endoscopic Rutgeerts; score. Therefore, acknowledging that many patients are not administered post-operative maintenance medications, we feel the placebo arm is justified.
Study NCT00439738 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HCTZ + Amlodipine
Description: * 12.5 mg HCTZ capsules~* 25 mg HCTZ capsules~* 5 mg amlodipine capsules~* 10 mg amlodipine capsules
Study NCT00439738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan/HCTZ
Description: * 160 mg film-coated valsartan tablets~* 320 mg film-coated valsartan tablets~* 12.5 mg HCTZ capsules~* 25 mg HCTZ capsules
Study NCT04411563 — intervention group
Intervention type: OTHER
Intervention: Taking biological samples
Description: Taking blood samples for biochemical and epigenetic analysis
Study NCT03316352 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Landmark-guided paramedian technique spinal anesthesia
Description: Landmark-guided paramedian technique will be used. Spinal anesthesia will be done using conventional landmark-guided paramedian technique.
Study NCT03316352 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: A preprocedural ultrasound scan will be done using Portable Echocardiography system (Vivid-i, GE healthcare) with 4C-RS convex probe (2.0-5.5 MHz Frequency range).
Study NCT03316352 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5% heavy bupivacaine
Description: During spinal anesthesia, 0.5% heavy bupivacaine will be administered into intrathecal space. The dose of local anesthetic injected for spinal anesthesia will be at the discretion of the attending anesthesiologist. The dose range of intrathecal bupivacaine will be between 12 and 16 mg.
Study NCT03316352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% heavy bupivacaine
Description: During spinal anesthesia, 0.5% heavy bupivacaine will be administered into intrathecal space. The dose of local anesthetic injected for spinal anesthesia will be at the discretion of the attending anesthesiologist. The dose range of intrathecal bupivacaine will be between 12 and 16 mg.
Study NCT02813772 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk formula NAN Sensitive, Nestle
Description: Infants randomized to group 1 will receive the milk formula NAN Sensitive, Nestle for a period of 4 weeks.
Study NCT02813772 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Milk formula Optipro, Nestle
Description: Infants randomized to group 1 will receive the milk formula NAN Optipro, Nestle for a period of 4 weeks.
Study NCT04058522 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rotator cuff rehabilitation classes
Study NCT04058522 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Individual Physiotherapy
Study NCT04058522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Injection
Description: Subacromial Injection 40mg/1ml
Study NCT04058522 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Injection
Description: Subacromial Injection 40mg/1ml
Study NCT02269358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: METHOTREXATE
Description: Infliximab therapy after escalation. SC methotrexate at 15 mg/m2 , not to exceed 25 mg/m2 per week for 4 weeks. Patients in remission after 4 weeks reduce their dose by halve. patients not in remission will continue the full dose until 12 weeks.
Study NCT01468987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2605541
Study NCT01468987 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Study NCT01468987 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Study NCT01468987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro
Study NCT00787787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: Given PO
Study NCT00787787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Given PO
Study NCT00177515 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: video doctor, computer module
Description: computerized counseling about emergency contraception and peri-conception folate
Study NCT00177515 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: video doctor, computer module
Description: computerized counseling about emergency contraception and peri-conception folate
Study NCT04151459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Use Metformin for 3 months to treat PCOS
Study NCT03748524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Influenza Vaccine
Description: Influenza Vaccine,Quadrivalent SIngle vaccination all participants at day 0
Study NCT04187833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 480mg intravenously every 4 weeks (28 days)
Study NCT04187833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: 1mg orally daily
Study NCT02872259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB324+pembrolizumab
Description: Combination
Study NCT02872259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB324+dabrafenib and trametinib
Description: Combination
Study NCT02872259 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pembrolizumab
Description: Monotherapy
Study NCT02872259 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dabrafenib and trametinib
Description: Combination
Study NCT04148495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo of acetaminophen IV
Description: Mophine IV: Initial loading dose of 0.1 mg/kg (ensuring that the maximum dose of 10 mg is not exceeded) followed by bolus of 0.05 mg/kg every 10 minutes (taking care not to exceed the maximum dose of 5 mg) as reported by the recommandation of experts of the french society of urgency care.~Placebo of acetaminophen IV: Sodium chloride 0.9%
Study NCT04148495 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetaminophen IV
Description: Mophine IV: Initial loading dose of 0.1 mg/kg (ensuring that the maximum dose of 10 mg is not exceeded) followed by bolus of 0.05 mg/kg every 10 minutes ((taking care not to exceed the maximum dose of 5 mg) as reported by the recommandation of experts of the french society of urgency care.~Acetaminophen IV: 1 g
Study NCT03365245 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Microperimetry
Description: Microperimetry is performed at three different days
Study NCT03365245 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: automated visual field
Description: Automated visual field ist performed at three different days
Study NCT02736448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: oral low dose of capecitabine
Study NCT02736448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu-PRRT
Description: Lu-PRRT (at 3.7Gbq per cycle x 7 cycles)
Study NCT03979404 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Theta Burst Stimulation
Description: The Magstim Rapid2 Magnetic Stimulator (Magstim ®, UK) will be used to administer active TBS.
Study NCT03007875 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: high-activity natural killer
Description: Each treatment: 8\~10 billion cells in all, transfuion in 3 times, i.v.
Study NCT01055327 — intervention group
Intervention type: DRUG
Intervention: Lamotrigine monotherapy
Description: Exposure to lamotrigine monotherapy in the first trimester of pregnancy (time period from first day of menstrual period to 12th week of gestation).
Study NCT01055327 — intervention group
Intervention type: DRUG
Intervention: No anti-epileptic drug exposure
Description: No exposure to anti-epileptic drugs in the first trimester of pregnancy (time period from first day of menstrual period to 12th week of gestation).
Study NCT01055327 — intervention group
Intervention type: DRUG
Intervention: Non lamotrigine anti-epileptic drug monotherapy
Description: Exposure to non lamotrigine monotherapy (with or without valproate) during the first trimester of pregnancy (time period from the first day of the menstrual period to the 12th week of gestation)
Study NCT05042297 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Combined posterior and anterior ring fixation: Active comparator. Isolated posterior ring fixation: Experimental intervention
Description: Reduction of the posterior ring was either closed reduction in SI joint dislocations \& fracture-dislocations and sacral fractures or open reduction in iliac wing fractures through the lateral window of the ilioinguinal approach. Anterior pelvic ring reduction and fixation in the combined APR fixation group was done via the classic Pfannenstiel approach or extension more lateral \& completing the anterior intrapelvic approach. Fixation was via pubic rami plating.
Study NCT05042297 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined posterior and anterior ring fixation: Active comparator. Isolated posterior ring fixation: Experimental intervention
Description: Reduction of the posterior ring was either closed reduction in SI joint dislocations \& fracture-dislocations and sacral fractures or open reduction in iliac wing fractures through the lateral window of the ilioinguinal approach. Anterior pelvic ring reduction and fixation in the combined APR fixation group was done via the classic Pfannenstiel approach or extension more lateral \& completing the anterior intrapelvic approach. Fixation was via pubic rami plating.
Study NCT02373072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06649751
Description: Subjects completing all three treatment periods will be administered two doses. Doses: 0.75mg, 1.5mg, 3mg, 6mg, 9mg. Tablets in the form of 0.25mg or 1 mg.
Study NCT02373072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethobenzamide Hydrochloride
Description: 300mg TID, Capsules. Optional in both Cohorts.
Study NCT02373072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects completing all three treatment periods will be receiving placebo once.
Study NCT02756897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO
Study NCT02756897 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02756897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study NCT03375684 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional chest physiotherapy
Description: Programme will include diaphragmatic breathing exercise, thoracic expansion exercises, incentive spirometer exercise (Triflo), oscillatory PEP (Flutter), postural drainage and coughing tecniques.
Study NCT03375684 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional chest physiotherapy
Description: Programme will include diaphragmatic breathing exercise, thoracic expansion exercises, incentive spirometer exercise (Triflo), oscillatory PEP (Flutter), postural drainage and coughing tecniques.
Study NCT04308135 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Neuro-radiological tools:
Description: MRI brain: to measure white matter~c) Ultrasonographic examination of extracranial vessels: The intimal medial thickness of the common carotid artery (CCA-IMT) will be measured in B-mode. The carotid arteries will be evaluated for the presence of atherosclerotic lesions (plaques) either soft or hard .The residual lumen and degree of stenosis will be measured. The peak systolic velocity will be detected.
Study NCT04308135 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: cognitive tests
Description: All patients will be evaluated for global cognitive assessment by: Montreal Cognitive Assessment (MoCA) (Arabic version) Visuospatial skills will be assessed by Clock Drawing Tests from MoCA test and copy the intersecting pentagons from Addenbrooke's test (Arabic version) Language will be examined by semantic fluency from Addenbrooke's test (Arabic version) and similarities from Wechsler Adult Intelligence Scale (WAIS) Attention will be evaluated by digit span from Wechsler test),and by the number of seconds needed to sequence numbers using a pencil (Trail making test A) from MoCA test . For the evaluation of memory, participants will complete Wechsler memory subset~, and the investigators also will use their three-item recall from the Mini-Mental State Examination( MMSE). Executive functions will be measured by Wisconsin card sorting test and also verbal fluency test from Addenbrooke's test. Frontal Assessment Battery (FAB) scale
Study NCT04308135 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: lab investigations
Description: Each patient will undergo full lab investigations:\[lipid profile ,complete blood count, uric acid ,Hemoglobin A1c (HbA1c), liver functions, renal functions, and electrolytes\]
Study NCT02736448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SS-LAR
Description: long acting octreotide or lanreotide
Study NCT04308135 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Beck depression inventory (BDI)(Arabic version)
Description: Clinical Tool for depression
Study NCT04308135 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical Tools for Urinary symptoms:
Description: the International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF) Scale (Arabic version)
Study NCT04308135 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Freezing of gait questionnaire
Description: Clinical Tools for Gait (in on and off state ), Gait will be assessed by:~* .Freezing of gait questionnaire~* Berg balance scale.~* 10 meter walk test .~* Timed up and go test.
Study NCT04308135 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: non-motor symptoms scales (NMSS).
Description: Clinical Tool for assessment of non-motor symptoms of PD
Study NCT03854227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06939999 dose escalation
Description: PF-06939999 orally at escalating doses on a continuous basis
Study NCT03854227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06939999 monotherapy
Description: PF-06939999 at the recommended Phase 2 dose orally on a continuous basis
Study NCT03854227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06939999 in combination with docetaxel
Description: PF-06939999 orally on a continuous basis in combination with docetaxel
Study NCT04308135 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Movement Disorders Society- Unified Parkinson's Disease Rating Scale (MDS-UPDRS):
Description: Clinical Tools for assessment of the neurological severity and stage of disease Clinical Tool for assessment of the neurological severity and stage of disease during OFF and ON states, Hoehn and Yahr scale. The presence of lower limb parkinsonism will be determined by a two-point difference between upper limb and lower limb scores of bradykinesia, rigidity or postural instability from part III of the MDS-UPDRS. Patients will be examined in the early morning, in 'OFF' state, with MDS-UPDRS, Hoehn and Yahr and freezing of gait questionnaire(FOG-Q) scales. Immediately afterwards, they will take their regular first dose of levodopa. After 1 hour, patients will be examined again with the same tests and scales.~Response to levodopa will be determined as patients who reached a percentage reduction exceeding 25% in part III of the MDS-UPDRS
Study NCT04308135 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ELIZA for alpha-synuclein
Description: measuring serum of alpha-synuclein, tau and their autoantibodoies
Study NCT04308135 — intervention group
Intervention type: OTHER
Intervention: transcranial color-coded duplex(TCCD)
Description: TCCD using phase array 2.4 Hz probe for evaluation of cerebral vasomotor reactivity (CVR) by measuring the Breath holding index(BHI),flow velocities and pulsatility index of middle cerebral artery and posterior cerebral artery on both sides.
Study NCT04308135 — intervention group
Intervention type: OTHER
Intervention: extracranial carotid duplex
Description: to assess atherosclerosis, stenosis of carotids
Study NCT04308135 — intervention group
Intervention type: OTHER
Intervention: The Arabic version of Parkinson's Disease Questionnaire( PDQ-39)
Description: Clinical tool for quality of life of PD patients